US-based Biomedical Advanced Research and Development Authority (BARDA) has partnered with Regeneron on the Covid-19 monoclonal antibody vaccine clinical development programme.
A part of the US Government鈥檚 Strategic Preparedness and Response division, BARDA has entered the partnership as part of Project NextGen. The project plans to leverage public-private partnerships to develop vaccines and therapies for Covid-19 SARS-CoV-2 and other future strains.
There has been an increased demand for Covid-19 vaccines that target the new variants, specifically Omicron, after the European Medicines Agency鈥檚 (EMA) decision to seek SARS-CoV-2 XBB 1.5 Omicron subvariant Covid-19 vaccines.
As per the current agreement, Regeneron will independently invent an antibody candidate for Covid-19. Following this, both parties will evaluate the further development of the candidate. BARDA will then fund up to $326m for the vaccine development.
In a , Regeneron CEO Leonard S Schleifer said: 鈥淎lthough Covid-19 has moved to an endemic stage, many people 鈥� including those with immunocompromising conditions 鈥� continue to face exposure that impacts their everyday life and could cause serious health consequences.
鈥淎merican biopharmaceutical companies in record time, successfully changing the course of the pandemic, and we鈥檙e gratified that the US Government continues to support early research from this uniquely innovative industry.鈥�
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe current partnership expands on the previous $450m agreement between BARDA and Regeneron to supply the Covid-19 vaccine.
BARDA also has a collaboration agreement with Regeneron to develop a portfolio of antibodies to target ten public-risk-causing pathogens, including influenza. Recently, BARDA ordered smallpox and mpox vaccines from as part of its preparedness response.
